COMMUNIQUÉS West-GlobeNewswire

PetMed Express, Inc. Announces Strategic Updates to Executive Leadership Team
03/06/2024
Caroline Conegliano appointed Chief Operating Officer Umesh Sripad appointed Chief Digital and Technology Officer Company Announces CFO transition DELRAY BEACH, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- PetMed Express, [...]
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
03/06/2024
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves [...]
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
03/06/2024
Sherry Korczynski joins the leadership team as Senior Vice President, Sales and Marketing Dr. Stephen Wargacki promoted to Chief Science Officer Cassie Jung named Chief Operating Officer WARREN, N.J., June 03, 2024 ( [...]
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
03/06/2024
MENLO PARK, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, [...]
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/2024
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response consistent with the [...]
ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
03/06/2024
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) The combination showed substantial antileukemic activity with deep [...]
AVRICORE HEALTH CORPORATE UPDATE – COMPANY ACHIEVES PROFITABILITY
03/06/2024
VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) reports on results for the first three months of 2024, the first period of net [...]
Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting
03/06/2024
Tonmya treatment was associated with improvement in depressive symptoms as measured by the Beck Depression Inventory-II In addition, post-hoc analyses showed improvement in depression, anxiety, memory and energy items [...]
Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing
03/06/2024
Collaboration aims to enhance biomanufacturing reliability, scalability and efficiency Autonomous humanoids designed to complement human labor and enhance productivity through 24/7 operational capabilities Beyond’s Hive [...]
Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer
03/06/2024
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE [...]
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
03/06/2024
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s disease ~ ~ Receiving [...]
Kraig Biocraft Laboratories Announces BAM-1 Spider Silk Hybrids are in Production
03/06/2024
ANN ARBOR, Mich., June 03, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that Kraig Labs is now in production with its BAM-1 recombinant spider [...]
Prelude Therapeutics to Participate in Upcoming Healthcare Conferences
03/06/2024
WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming [...]
Fortrea to Present at the Jefferies Global Healthcare Conference
03/06/2024
DURHAM, N.C., June 03, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chairman and Chief Executive Officer, Tom Pike and Chief Financial [...]
HighLife Receives IDE Approval to Initiate US Pivotal Clinical Study for treatment of Mitral Regurgitation
03/06/2024
HighLife Receives IDE Approval to Initiate US Pivotal Clinical Study for treatment of Mitral Regurgitation Paris, June 3 rd 2024 - HighLife SAS, a medtech company focused on the development of a novel Trans-Septal [...]
Aruna BIO Announces Appointment of Lynn Swann to its Board of Directors
03/06/2024
BOSTON and ATHENS, Ga., June 03, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced the appointment of Lynn Swann [...]
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03/06/2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc . (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that [...]
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/2024
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients HOUSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Bio-Path [...]
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
03/06/2024
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily [...]

Pages